Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

NCT06494150 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Low Grade Ovarian Serous Adenocarcinoma

Interventions

DRUG: nab-Sirolimus
DRUG: Fulvestrant

Sponsor

University of Oklahoma

Collaborators

[object Object]